Tag: Market Access
DARWIN EU 2.0 & JCA PICO Strategy: Streamlining Multi-State RWE
Mastering DARWIN EU 2.0 Interoperability for JCA Compliance: The Technical Blueprint for Multi-State Real-World Evidence The European market access landscape is undergoing its most profound structural disruption since the centralization of regulatory approvals. The rollout of the European Union Health Technology Assessment (EU-HTA) regulation has effectively shifted the goalposts for pharmaceutical manufacturers. No longer can…
AI for Predicting Market Access Barriers in Rare Diseases
AI for Predicting Market Access Barriers in Rare Diseases Predicting market access barriers in rare diseases is a complex process. AI is helping simplify this process by identifying regulatory, pricing, and reimbursement challenges before they emerge. This article explores how AI can support pharma and biotech companies in improving market access planning for rare disease…
Will Real-World Evidence (RWE), Decide Your Drug’s Price in 2025?
Real-World Evidence (RWE) Will Decide Your Drug’s Price in 2025 Drug pricing in 2025 is no longer driven solely by clinical trial data. Health authorities and payers now demand proof that drugs perform well in everyday use. Real-World Evidence (RWE) has become the backbone of value-based pricing. Its ability to reflect how patients respond outside…
Why Global Health Agencies Are Demanding RWE in 2025
Why Global Health Agencies Are Demanding Real-World Evidence in 2025 And What It Means for Market Access In 2025, healthcare is no longer defined by clinical trial results alone. Across the globe, regulatory bodies and health technology assessment (HTA) agencies are making one thing crystal clear: Real-World Evidence (RWE) is now a non-negotiable requirement for…
